Cancer panels use next generation sequencing (NGS) technology to target specific genes or mutations that have established relevancy to a particular cancer phenotype. NGS facilitates sequencing of large genomic regions, high numbers of genes, and/or high numbers of samples in a single, efficient and cost-effective assay. In addition, NGS provides significantly higher sensitivity than traditional techniques, which permits the discovery of rare somatic mutations, many of which have been identified as important cancer drivers.
GENEWIZ offers a number of different cancer panels to provide a complete solution from experimental design to advanced bioinformatics analysis.
Discovery Cancer Panels
Amplicon Cancer Panel
|Sequencing Platform||Illumina MiSeq or HiSeq||Illumina MiSeq|
|Cancer Types Assayed||19 distinct gene panels, each assays a specific cancer (organ) type||Single gene panel assays multiple cancer types|
|Genes Covered||≈150 - 400||48|
|Genomic Variation Detection||
|Target Regions||≈ 2 - 5.4 Mb, consisting of all exons, UTRs, and relevant intron regions||≈35 Kb, consisting of mutational hot spots|
|Average Depth||> 100x*||> 100x*|
|Target Enrichment||Agilent SureSelect Targeted Enrichment||Illumina Targeted Amplicon Sequencing|
|DNA Input||> 100 ng||> 250 ng|
GENEWIZ is a certified service provider for Illumina NGS platforms and the PacBio Sequel. Please visit our NGS Platforms page for more information.